JP Morgan Chase
AUTL

JP Morgan Chase’s Autolus Therapeutics AUTL Stock Holding History

JP Morgan Chase’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,000
Closed -$51K – 7334
2024
Q1 		$51K Buy
+8,000
New +$49.9K ﹤0.01% 5932

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's AUTL Position: Q1 2026 in Review

JP Morgan Chase reduced its Autolus Therapeutics (AUTL) stake by 4.5% in Q1 2026, selling an estimated $66.6K and leaving 935,403 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4490.

JP Morgan Chase first reported a position in AUTL in Q4 2019 and has held it in 26 quarters since. The position peaked at $8.85M in Q3 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • JP Morgan Chase held 935,403 shares of Autolus Therapeutics worth $1.19M as of Q1 2026.
  • JP Morgan Chase sold 43,872 Autolus Therapeutics shares in Q1 2026, an estimated $66.6K.
  • Autolus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4490 holding.
  • JP Morgan Chase first reported a position in Autolus Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • JP Morgan Chase's Autolus Therapeutics position peaked at $8.85M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.